Toll Free 1-888-590-9839 info@modernveterinarytherapeutics.com

  • Modern Veterinary News

    Modern Veterinary Therapeutics News

     

    November 12, 2016 - Modern Veterinary Therapeutics, LLC announces that the Veterinary Drugs Directorate (VDD) has approved Cloprostenol Veyx SWTM (cloprostenol injection - 175μg/2mL) in Canada. Cloprostenol Veyx SWTM, approved for use in swine, is presented in a 50mL vial. Cloprostenol Veyx SWTM is a synthetic prostaglandin that induces farrowing in sows and gilts. Parturition and piglet viability are normal when Cloprostenol Veyx SWTM is administered as early as 1 or 2 days before the expected farrowing date. "Modern Veterinary Therapeutics, LLC is pleased to announce this new approval in Canada demonstrating our commitment to expanding our reproductive production animal product line" said Dr. Cuong Tu Ba, President of Modern Veterinary Therapeutics, LLC.
    Miami, FL January 6, 2016 Modern Veterinary Therapeutics, LLC announces that the Veterinary Drugs Directorate (VDD) has approved Nerfasin 100TM (xylazine injection - 100mg/mL) in Canada. Nerfasin 100TM, presented in a 50mL vial, is indicated for use in horses when it is desirable to produce a state of sedation accompanied by a shorter period of analgesia. "Modern Veterinary Therapeutics, LLC is pleased to announce this new approval in Canada which further expands our veterinary line of sedative and analgesic products," said Dr. Cuong Tu Ba, President of Modern Veterinary Therapeutics, LLC.
    Miami, FL October 28, 2015 — Modern Veterinary Therapeutics, LLC announces that the Veterinary Drugs Directorate (VDD) has approved Nerfasin 20TM (xylazine injection – 20mg/mL) in Canada. Nerfasin 20TM, presented in a 25mL vial, is indicated for use in dogs, cats, and cattle when it is desirable to produce a state of sedation accompanied by a shorter period of analgesia. “Modern Veterinary Therapeutics, LLC is pleased to announce this new approval in Canada which further expands our veterinary line of sedative and analgesic products,” said Dr. Cuong Tu Ba, President of Modern Veterinary Therapeutics, LLC.
    Miami, FL October 1, 2015  — Modern Veterinary Therapeutics, LLC announces that the Veterinary Drugs Directorate (VDD) has approved Ketoprofen VTM (ketoprofen injection - 100mg/mL) in Canada. Ketoprofen VTM, presented in 100mL and 250mL vials, is anonsteroidal anti-inflammatory agent possessing anti-inflammatory, analgesic, and antipyretic properties. Ketoprofen VTM is approved for use in horses, swine, and cattle. Ketoprofen is the only NSAID approved in Canada with NO milk withdrawal period.  "Modern Veterinary Therapeutics, LLC is pleased to announce this new approval in Canada which further expands our line of products for the production animal industry, providing incredible savings to Canadian veterinarians and producers alike" said Dr. Cuong Tu Ba, President of Modern Veterinary Therapeutics, LLC.
    Miami, FL July 31, 2014 — Modern Veterinary Therapeutics, LLC announces that the USDA-Center for Veterinary Biologics has approved our Canine Parvovirus-Coronavirus Antigen Test Kit. This new Canine Parvovirus-Coronavirus Antigen Test Kit is the first rapid in-clinic chromatographic immunoassay test in the U.S. market for the qualitative detection of both Coronavirus and Parvovirus antigens in canine feces simultaneously. Canine Parvovirus and Coronavirus cause sporadic outbreaks of vomiting and diarrhea in dogs. The rate of simultaneous infection of CPV and CCV is up to 25% of CPV infections (Evermann 1989,) and simultaneous infection is much more severe and fatal than a single infection. The clinical sign of CCV is usually mild enteritis, and some deaths have been reported in young dogs. The clinical signs of CPV and CCV are very similar (diarrhea and vomiting) making it difficult to differentiate which virus is the causative agent by clinical signs alone. The Canine Parvovirus-Coronavirus Antigen Test Kit is highly sensitive and specific, providing a positive or negative result in 5 minutes to help practitioners recognize these viruses in the clinic. The tests are easy to use, can be stored at room temperature, and have a 2-year shelf life.
    Miami, FL June 15, 2014 — Modern Veterinary Therapeutics, LLC announces that the Veterinary Drugs Directorate (VDD) has approved  HYMATILTM (tilmicosin injection - 300 mg/mL) in Canada. HYMATILTM, presented in a 100mL multidose vial, is indicated for the treatment of bovine respiratory disease (BRD) associated with Mannheimia (Pasteurella) haemolytica and Pasteurella multocida and for the reduction of morbidity associated with bovine respiratory disease (BRD) in feedlot calves, caused by Mannheimia (Pasteurella) haemolytica and Pasteurella multocida, during the first 30 days in the feedlot, when administered at the time of arrival. HYMATILTMis indicated for the treatment of pneumonic pasteurellosis in lambs associated with Mannheimia (Pasteurella) haemolytica. "Modern Veterinary Therapeutics, LLC is pleased to announce this new approval in Canada demonstrating our commitment to further expanding our bovine product line including entrance into the beef cattle industry as well," said Dr. Cuong Tu Ba, President of Modern Veterinary Therapeutics, LLC.
    Miami, FL January 31, 2014—Modern Veterinary Therapeutics, LLC announces that the Veterinary Drugs Directorate (VDD) has approved CLOPROSTENOL VEYXTM (cloprostenol injection - 250 mg/mL) in Canada. CLOPROSTENOL VEYXTM is presented in 10mL, 20mL, and 50mL vials and a 12x50mL vial value package. CLOPROSTENOL VEYXTM's ability to shorten the life span of the corpus luteum makes it efficient for multiple therapeutic indications including treating certain clinical conditions which delay breeding, manipulating the estrous cycle to better fit specific management practices, and inducing abortion. For controlled breeding, the luteolytic action of CLOPROSTENOL VEYXTM can be used to schedule estrus and ovulation for animals in order to control when cycling cows or heifers can be bred. "Modern Veterinary Therapeutics, LLC is pleased to announce this new approval in Canada demonstrating our commitment to expanding our focus to include production animals in addition to our existing companion animal and equine product lines" said Dr. Cuong Tu Ba, President of Modern Veterinary Therapeutics, LLC.
    Miami, FL April 10, 2012—Modern Veterinary Therapeutics, LLC announces that the Veterinary Drugs Directorate (VDD) has approved RESPIPULMINTM (Clenbuterol hydrochloride syrup) in Canada for the treatment of respiratory disease in horses. RESPIPULMINTM is presented in a 355 mL bottle of syrup containing 0.025 mg of clenbuterol hydrochloride per mL. RESPIPULMINTM syrup is an orally administered beta-2 agonist for the management of airway obstruction. Bronchodilators relieve the airway obstruction associated with inflammatory airway disease and they work most effectively when combined with allergen and dust avoidance or corticosteroid administration. “Modern Veterinary Therapeutics, LLC is pleased to report this new approval in Canada demonstrating our commitment to become a strategic and trusted partner to veterinarians in Canada” said Dr. Cuong Tu Ba, President and founder of Modenr Veterinary Therapeutics, LLC.        
    Miami, FL - (March 8, 2012) - Modern Veterinary Therapeutics, LLC announces today that the Australian Pesticides and Veterinary Medicines Authority (APVMA) has approved CEPESEDAN, CEPETOR and REVERTOR in Australia. CEPESEDAN (detomidine) is indicated for use as a sedative and analgesic to facilitate minor surgical and diagnostic procedures in mature horses and yearlings. The product is presented in 5ml and 20ml vials. CEPETOR (medetomidine) is indicated for use as sedative and analgesic to facilitate clinical examinations, clinical procedures, minor surgical procedures in dogs and cats. The product is presented in 10ml vial. REVERTOR (atipamezole) is indicated for the reversal of the clinical effects of the sedative and analgesic agent, medetomidine hydrochloride in dogs and cats. The product is presented in 10ml vial. These three products will be presented and featured at the Australian Veterinary Association (AVA) Annual Conference 2012 in May in Canberra at the National Convention Center on May 20-25. “As we continue our aggressive global expansion strategy, Modern Veterinary Therapeutics is very excited to be entering the Australian market with our pharmaceutical product line.” Said Dr. Cuong Tu Ba, Founder and President of Modern Veterinary Therapeutics, LLC.
    Miami, FL - (October 04, 2010) - Modern Veterinary Therapeutics, LLC (USA) and Biogal Galed Labs (Israel) announce today that the USDA-Center for Veterinary Biologics has approved Canine VacciCheck diagnostic kit. Canine VacciCheck is indicated for the detection of antibodies to infectious canine hepatitis, canine parvovirus and canine distemper in dog whole blood or serum. “At last veterinarians don’t have to choose between good medical practice and the revenue for their clinics. Canine VacciCheck, the first in-clinic antibody diagnostic test for all three major canine viral infections, is a practical solution that allows the veterinarians to keep both the expertise and the revenue in the clinic as well as the same frequency of visits by the pet owners. Canine VacciCheck is based on the patented ImmunoComb technology and is offered with CombScan software which allows a reading of the results within only a few seconds. Modern Veterinary Therapeutics LLC is pleased to begin offering this new product that represents the most significant innovation in the antibody diagnostic market in the last 10 years”, said Dr Cuong Tu Ba, President and Founder of Modern Veterinary Therapeutics.
    Miami, FL - (November 29, 2009) - Modern Veterinary Therapeutics, LLC announces today that the Veterinary Drugs Directorate (VDD) has approved REVERTOR in Canada. REVERTOR is indicated for the reversal of the clinical effects of the sedative and analgesic agent, medetomidine hydrochloride, in dogs. The product will be presented in 10 mL vial. "Modern Veterinary Therapeutics LLC is pleased to begin offering this product which represents our third approval within a month and our fifth approval in less than a year in Canada. This track of records speaks for itself about the technical and regulatory expertise of our young company and demonstrates one more time our commitment to serve Veterinarians in Canada”, said Dr Cuong Tu Ba, Founder and President of Modern Veterinary Therapeutics, LLC.
    Miami, FL - (November 14, 2009) - Modern Veterinary Therapeutics, LLC announces today that the Veterinary Drugs Directorate (VDD) has approved CEPETOR in Canada. CEPETOR is indicated for use as a sedative and analgesic to facilitate clinical examinations, clinical procedures, minor surgical procedures with the exception of those requiring muscle relaxation, and minor dental procedures where intubation is not required, in dogs over 12 weeks of age. The product will be presented in 10 mL vial. “In our continuing effort to offer the most comprehensive and cost effective line of injectables in the critical care and sedative veterinary market, Modern Veterinary Therapeutics LLC is pleased to begin offering this product which represents our fourth approval in less than a year in Canada. This continues to demonstrate our commitment to provide a broad based portfolio of products to Veterinarians in Canada”, said Dr Cuong Tu Ba, Founder and President of Modern Veterinary Therapeutics, LLC.
    Miami, FL - (October 29, 2009) - Modern Veterinary Therapeutics, LLC announces today that the Veterinary Drugs Directorate (VDD) has approved CEPESEDAN in Canada. CEPESEDAN is indicated for use as a sedative and analgesic to facilitate minor surgical and diagnostic procedures in mature horses and yearlings. The product will be presented in 5 mL and 20 mL vials. “These successive registrations of RESPIRAM, ImmunoComb-FIP and now CEPESEDAN in less than a year are the results of our aggressive strategy of expansion in Canada. Other products are in the final registration phase and will be offered very soon in Canada”, said Dr Cuong Tu Ba, Founder and President of Modern Veterinary Therapeutics, LLC.